Impact of 2018 ASCO/CAP guidelines on HER‐2 reporting categories of IHC and reflex FISH in breast cancer. Issue 11 (31st August 2020)

• Record Type: Journal Article
• Authors: Pasricha, Sunil; Menon, Vidya; Gupta, Gurudutt; Kamboj, Meenakshi; Sharma, Anila; Durga, Garima; Tripathi, Rupal; Batra, Ullas; Jajodia, Ankush; Koyyala, Venkata Pradeep Babu; Agrawal, Chaturbhuj; Doval, Dinesh C.; Mehta, Anurag
• Is Part Of: Breast journal. Volume 26:Issue 11(2020)
• Page Start: 2213
• Page End: 2216
• Publication Date: 2020-08-31
• Subjects: ASCO/CAP -- HER‐2 guidelines -- invasive breast cancer; Breast -- Diseases -- Periodicals; Breast -- Cancer -- Periodicals; 618.19
• DOI: 10.1111/tbj.14031
• Languages: English
• ISSNs: 1075-122X

Abstract

Abstract: Human epidermal growth factor receptor 2 (HER‐2) is an established prognostic and predictive biomarker for breast cancer. To ensure accuracy and uniformity for HER‐2 testing, ASCO/CAP published guidelines in 2007 which were updated in 2013 and recently in 2018. In this first study from Indian Oncology center, we evaluated the impact of 2018 ASCO/CAP guidelines. We found a substantial decrease in equivocal IHC cases ( P ‐value < .00001). On reclassification, a total of 5.6% cases from equivocal and positive categories (2013 guidelines) shifted to the negative FISH result category ( P ‐value < .0001), with adoption of 2018 guidelines and eliminated the double equivocal cases.